USP11 deubiquitinates GATA3 to suppress the growth and metastasis of luminal-type breast cancers
Tao Qian, Xiong Liu, Feng Bai, Qiyue He, Yipei Xu, Jiayi Zhang, Shiwen Zhang, Shaoling Ye, Yuchan Wang, Bin Peng, Kapanova Gulnara, Jasur Rizaev, Wei-Guo Zhu, Xingzhi Xu, Xin-Hai Pei · 2026
Read USP11 deubiquitinates GATA3 to suppress the growth and metastasis of luminal-type breast cancers by Tao Qian, Xiong Liu, Feng Bai, Qiyue He, Yipei Xu, Jiayi Zhang, Shiwen Zhang, Shaoling Ye, Yuchan Wang, Bin Peng, Kapanova Gulnara, Jasur Rizaev, Wei-Guo Zhu, Xingzhi Xu, Xin-Hai Pei (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13524610.txt.
Description
Qian and colleagues identified in 2026 a protein axis that restrains luminal breast cancers, the most common breast cancer type. The team studied USP11, an enzyme that removes ubiquitin tags from proteins, stabilising them.
USP11 suppressed growth and migration of luminal cells but not of basal-like cells. In mice it curbed luminal tumour growth and spread, yet promoted basal-like tumour formation, a striking split. Mechanistically, USP11 stabilises GATA3, a master regulator of luminal identity, by removing its ubiquitin tags. GATA3 then switches on genes for p27, a cell-cycle brake, and for the estrogen receptor. Removing GATA3 erased USP11's protective effects, and USP11 made luminal cells more sensitive to the drug tamoxifen. The authors name the USP11-GATA3 axis a guardian of luminal fate.
Catalog record
| CREATOR | Tao Qian, Xiong Liu, Feng Bai, Qiyue He, Yipei Xu, Jiayi Zhang, Shiwen Zhang, Shaoling Ye, Yuchan Wang, Bin Peng, Kapanova Gulnara, Jasur Rizaev, Wei-Guo Zhu, Xingzhi Xu, Xin-Hai Pei |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |